Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Kartos Therapeutics, Inc.

Clinical trials sponsored by Kartos Therapeutics, Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Hope for myelofibrosis patients: new drug combo aims to shrink spleens and ease symptoms Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

Hope for myelofibrosis patients: new drug combo aims to shrink spleens and ease symptoms

Disease control Recruiting now

This study tests whether adding navtemadlin to the standard drug ruxolitinib helps people with myelofibrosis who aren't getting enough benefit from ruxolitinib alone. About 600 adults with myelofibrosis will first take ruxolitinib, then those with a poor response will be randomly…

Phase 3 • Sponsor: Kartos Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC